RedHill and Cumberland Launch U.S. Talicia Rollout Following $4M Investment
RedHill and Cumberland Pharmaceuticals have initiated full U.S. sales and operational rollout of Talicia under their 70/30 joint commercialization entity, following Cumberland’s $4 million strategic investment. Talicia, the only FDA-approved all-in-one low-dose rifabutin H. pylori therapy with U.S. exclusivity through 2042, targets 1.6 million treated patients annually.
1. Joint Commercialization Launch
The Talicia launch has commenced under a jointly controlled entity owned 70% by RedHill and 30% by Cumberland, marking the operational rollout of the October 2025 agreement. Cumberland’s $4 million strategic investment supports accelerated market penetration and expanded reach across gastroenterology practices.
2. Talicia's Clinical and Market Profile
Talicia is the only FDA-approved, all-in-one low-dose rifabutin H. pylori therapy designed to overcome antibiotic resistance and is recommended as a first-line treatment in the 2024 American College of Gastroenterology guideline. It addresses infections affecting 35% of U.S. adults and an estimated 1.6 million patients treated annually.
3. Expansion and Global Opportunities
RedHill is exploring new market entries for Talicia in the UK and Middle East and is pursuing additional non-dilutive licensing revenue streams outside the U.S. to further broaden patient access and drive long-term growth.